30th May 2023

The University of Aberdeen Epidemiology Group is collaborating with BSAC to develop the first UK Antimicrobial Registry (UKAR). The UKAR Study team is delighted to announce that NHS Grampian and NHS Greater Glasgow and Clyde are open for recruitment of participants to the UK Antimicrobial Registry.

The first green light for the UKAR study was given on Friday 19th May 2023, from the exhibition hall of the BSAC Spring Conference. The UKAR team found the 2-day conference very interesting and informative. We enjoyed talking with people from all over the UK and Ireland. It was encouraging to hear the value and importance that so many of the conference speakers and delegates placed on the UK Antimicrobial Registry. Whilst Prof Gareth Jones (who spoke at the conference) and Rebecca Parr were talking with delegates about getting their site on board, Senior Study Coordinator Laura Moir was busy online, ensuring that everything was in place with the NHS Grampian site study team.

Hot on the heels of the NHS Grampian site came NHS Greater Glasgow and Clyde (GGC). We had been working closely with the team at site to ensure that everyone had completed their study, website and simulated data training. As the team at GGC had all the systems and processes in place they were able to hit the ground running and recruit their first participant within 3 days of green light. We are now looking forward to collecting vitally important data that will increase our understanding of antimicrobial usage and effectiveness against resistant organisms.

Dr Andrew Seaton, UKAR Study Principal Investigator at NHS GGC and member of the BSAC UKAR Steering Committee had this to say about the study,

“I’m delighted for our team to be part of this really important study that will give much needed real world data on new antimicrobial use and clinical outcomes. Importantly UKAR will also support evaluation of the NICE new antimicrobial de-linkage initiative, a world’s first for the UK. The University of Aberdeen team have done a really excellent job in setting up the study as well as training and supporting our team in Glasgow. We are looking forward to maximising recruitment and seeing the study roll out across the UK”.

The 11 eligible UKAR study drugs are listed below. If you are interested to learn more, contact the UKAR team (ukar@abdn.ac.uk), visit the UKAR study website or complete the UKAR Expression of Interest Form. The team will then get in touch to set up an informal Teams meeting to introduce ourselves, and discuss the best way to run the study at your site.

UKAR eligible study drugs

  • Cefiderocol*
  • Ceftaroline
  • Ceftazidime/avibactam*
  • Ceftobiprole
  • Ceftolozane/tazobactam
  • Dalbavancin
  • Delafloxacin
  • Eravacycline
  • Imipenem/cilastatin/relebactam
  • Meropenem/vaborbactam
  • Oritavancin

*Antimicrobial agents in the NICE de-linkage initiative.

GP? Pharmacist? Researcher? Social Scientist? Whatever field you work in, if you’re committed to fighting infection then we want you to join us as a BSAC Member.
Become a member

Having trouble finding what you're after?

Top